Royalty Pharma（RPD）株式概要Royalty Pharma plcは、バイオ医薬品ロイヤリティの買い手として、また米国のバイオ医薬品業界におけるイノベーションの資金提供者として事業を展開している。 詳細RPD ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長5/6過去の実績2/6財務の健全性3/6配当金2/6報酬当社が推定した公正価値より73.9%で取引されている 収益は年間38.77%増加すると予測されています リスク分析多額の負債を抱えている 1.71%の配当はフリーキャッシュフローで十分にカバーされていない すべてのリスクチェックを見るRPD Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€47.417.0% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture05b2016201920222025202620282031Revenue US$5.0bEarnings US$1.7bAdvancedSet Fair ValueView all narrativesRoyalty Pharma plc 競合他社Merck KGaASymbol: XTRA:MRKMarket cap: €57.9bDermapharm HoldingSymbol: XTRA:DMPMarket cap: €2.4bSartoriusSymbol: XTRA:SRT3Market cap: €14.3bZoetisSymbol: NYSE:ZTSMarket cap: US$33.4b価格と性能株価の高値、安値、推移の概要Royalty Pharma過去の株価現在の株価US$47.4152週高値US$49.0052週安値US$28.87ベータ0.421ヶ月の変化2.95%3ヶ月変化21.49%1年変化58.60%3年間の変化62.18%5年間の変化n/aIPOからの変化45.41%最新ニュースお知らせ • Jun 10Royalty Pharma plc Announces Resignation of Errol Bento Jose Trinidade De Souza as Director, Effective June 4, 2026Royalty Pharma Plc announced the resignation of Errol Bento Jose Trinidade De Souza as director of the company, with effect from June 4, 2026.お知らせ • Apr 17Royalty Pharma plc Declares Dividend for the Second Quarter 2026, Payable on June 10, 2026Royalty Pharma plc approved the payment of a dividend for the second quarter of 2026 of $0.235 per Class A ordinary share. The dividend will be paid on June 10, 2026, to shareholders of record at the close of business on May 15, 2026.お知らせ • Apr 16Royalty Pharma plc to Report Q1, 2026 Results on May 06, 2026Royalty Pharma plc announced that they will report Q1, 2026 results Pre-Market on May 06, 2026お知らせ • Apr 13Royalty Pharma plc, Annual General Meeting, Jun 04, 2026Royalty Pharma plc, Annual General Meeting, Jun 04, 2026. Location: 110 east 59th street, ny 10022, new york United Statesお知らせ • Mar 23Royalty Pharma plc Appoints Lucas Glass as Head of Artificial Intelligence, Effective April 2026Royalty Pharma plc announced the appointment of Lucas Glass as Head of Artificial Intelligence, effective April 2026. Lucas will lead the development and implementation of artificial intelligence capabilities across Royalty Pharma. Lucas most recently served as Senior Vice President of Technology at IQVIA, a global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, where he led enterprise architecture, domain architecture and platform engineering initiatives. Earlier in his career, Lucas held data science and statistical leadership roles at Routine Recovery and the U.S. Department of Justice. Lucas completed doctoral studies in statistics at Temple University, an MS in biostatistics from Drexel University and a BA in physics from Boston University.お知らせ • Mar 18Royalty Pharma plc Announces Executive AppointmentsRoyalty Pharma plc announced that Greg Butz will join Royalty Pharma as Executive Vice President, Partnering & Investments, effective June 2026. Greg joins Royalty Pharma from Bank of America, where he was the Global Co-Head of Healthcare Investment Banking. At Bank of America, Greg worked with public and private biopharma companies across a range of capital raising and strategic advisory transactions. Prior to his acting as Global Co-Head of Healthcare, Greg held Co-Head North American Healthcare Investment Banking and Head of Life Sciences Investment Banking roles at Bank of America. Greg graduated with a BA from Williams College and received an MBA from Dartmouth. In connection with hiring Mr. Butz, Chris Hite has been appointed Chairman, Partnering & Investments where he will continue to expand Royalty Pharma’s global relationship network and play a central role in transactions. Chris is a highly valued partner whose leadership, insight, and dedication have been instrumental to the growth and evolution of Royalty Pharma, as well as to the advancement of the broader royalty market. The company announced recent expansion of its leadership team, including the addition of Ken Sun as new Head of Asia. Together, Greg and Ken working with Chris Hite will be highly complementary and will enhance ability to originate and execute differentiated royalty transactions worldwide.最新情報をもっと見るRecent updatesお知らせ • Jun 10Royalty Pharma plc Announces Resignation of Errol Bento Jose Trinidade De Souza as Director, Effective June 4, 2026Royalty Pharma Plc announced the resignation of Errol Bento Jose Trinidade De Souza as director of the company, with effect from June 4, 2026.お知らせ • Apr 17Royalty Pharma plc Declares Dividend for the Second Quarter 2026, Payable on June 10, 2026Royalty Pharma plc approved the payment of a dividend for the second quarter of 2026 of $0.235 per Class A ordinary share. The dividend will be paid on June 10, 2026, to shareholders of record at the close of business on May 15, 2026.お知らせ • Apr 16Royalty Pharma plc to Report Q1, 2026 Results on May 06, 2026Royalty Pharma plc announced that they will report Q1, 2026 results Pre-Market on May 06, 2026お知らせ • Apr 13Royalty Pharma plc, Annual General Meeting, Jun 04, 2026Royalty Pharma plc, Annual General Meeting, Jun 04, 2026. Location: 110 east 59th street, ny 10022, new york United Statesお知らせ • Mar 23Royalty Pharma plc Appoints Lucas Glass as Head of Artificial Intelligence, Effective April 2026Royalty Pharma plc announced the appointment of Lucas Glass as Head of Artificial Intelligence, effective April 2026. Lucas will lead the development and implementation of artificial intelligence capabilities across Royalty Pharma. Lucas most recently served as Senior Vice President of Technology at IQVIA, a global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, where he led enterprise architecture, domain architecture and platform engineering initiatives. Earlier in his career, Lucas held data science and statistical leadership roles at Routine Recovery and the U.S. Department of Justice. Lucas completed doctoral studies in statistics at Temple University, an MS in biostatistics from Drexel University and a BA in physics from Boston University.お知らせ • Mar 18Royalty Pharma plc Announces Executive AppointmentsRoyalty Pharma plc announced that Greg Butz will join Royalty Pharma as Executive Vice President, Partnering & Investments, effective June 2026. Greg joins Royalty Pharma from Bank of America, where he was the Global Co-Head of Healthcare Investment Banking. At Bank of America, Greg worked with public and private biopharma companies across a range of capital raising and strategic advisory transactions. Prior to his acting as Global Co-Head of Healthcare, Greg held Co-Head North American Healthcare Investment Banking and Head of Life Sciences Investment Banking roles at Bank of America. Greg graduated with a BA from Williams College and received an MBA from Dartmouth. In connection with hiring Mr. Butz, Chris Hite has been appointed Chairman, Partnering & Investments where he will continue to expand Royalty Pharma’s global relationship network and play a central role in transactions. Chris is a highly valued partner whose leadership, insight, and dedication have been instrumental to the growth and evolution of Royalty Pharma, as well as to the advancement of the broader royalty market. The company announced recent expansion of its leadership team, including the addition of Ken Sun as new Head of Asia. Together, Greg and Ken working with Chris Hite will be highly complementary and will enhance ability to originate and execute differentiated royalty transactions worldwide.お知らせ • Mar 03Royalty Pharma plc Appoints Kenneth Sun as Senior Vice President and Head of Asia, Effective May 2026Royalty Pharma plc announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. Ken will be based in Hong Kong and lead the company’s royalty business in Asia. Ken joins Royalty Pharma from Morgan Stanley, where he was Head of Asia Pacific Healthcare Investment Banking. Asia-based biotechnology companies are now prolific creators of innovative therapeutics. In 2025, the out-licensing of Chinese medicines alone comprised over $130 billion of announced transaction value, up from approximately $14 billion in 2021, as multinational pharmaceutical companies increasingly recognized the value of this innovation. This momentum is expected to continue into 2026 and beyond, as modalities, therapeutic areas and deal structures out of Asia become increasingly innovative, comprehensive and diverse. The royalties from these transactions are creating a new market opportunity for royalty-based funding. Royalty Pharma will partner with biotechnology innovators to build the royalty market in greater Asia, just as Royalty Pharma played a foundational role in establishing the biopharma royalty market in the west by working closely with universities, research institutions and biopharma companies over two decades ago. In his previous role as Managing Director, Head of Asia Pacific Healthcare Investment Banking at Morgan Stanley, Ken led the establishment of the bank’s leadership position in China. He advised a diverse spectrum of strategic clients, including biotech, medtech, CRO, pharmaceutical and healthcare service companies. Ken successfully led origination and execution of notable and industry defining healthcare transactions across IPOs, M&A, and biotech licensing advisory, with a primary focus on Greater China. He brings more than 18 years of investment banking experience, having previously worked at China Renaissance and BNP Paribas. Ken holds a Bachelor’s degree in Electrical Engineering from Queen’s University, Canada.お知らせ • Feb 11Royalty Pharma plc Provides Earnings Guidance for the Full Year 2026Royalty Pharma plc provided earnings guidance for the full year 2026. For the period, the company expects 2026 Portfolio Receipts to be between $3,275 million and $3,425 million. Portfolio Receipts guidance represents expected growth of 14% to 16% in 2025. Royalty Pharma’s full year 2025 guidance reflects a negligible estimated foreign exchange impact to Portfolio Receipts, assuming current foreign exchange rates prevail for the rest of 2025.お知らせ • Jan 21Royalty Pharma plc to Report Q4, 2025 Results on Feb 11, 2026Royalty Pharma plc announced that they will report Q4, 2025 results Pre-Market on Feb 11, 2026お知らせ • Jan 09Royalty Pharma plc Declares Dividend on Class A Ordinary Share for the First Quarter of 2026, Payable on March 10, 2026Royalty Pharma plc announced that its board of directors has declared a dividend for the first quarter of 2026 of $0.235 per Class A ordinary share, reflecting a 6.8% increase in the company’s quarterly dividend over the previous quarter’s dividend. The dividend will be paid on March 10, 2026 to shareholders of record at the close of business on February 20, 2026.お知らせ • Nov 06Royalty Pharma plc Announces Earnings Guidance for the Full Year 2025Royalty Pharma plc announced earnings guidance for the full year 2025. For the period, the company expects 2025 Portfolio Receipts to be between $3,200 million and $3,250 million (previously $3,050 million to $3,150 million), representing expected growth of 14% to 16% (previously 9% to 12%).お知らせ • Oct 17Royalty Pharma plc Approves Dividend on Class A Ordinary Share for Fourth Quarter of 2025 , Payable on December 10, 2025The board of directors of Royalty Pharma plc approved the payment of a dividend for the fourth quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid on December 10, 2025, to shareholders of record at the close of business on November 14, 2025.お知らせ • Oct 02Royalty Pharma plc to Report Q3, 2025 Results on Nov 05, 2025Royalty Pharma plc announced that they will report Q3, 2025 results Pre-Market on Nov 05, 2025お知らせ • Sep 30Royalty Pharma plc Appoints Ted W. Love as Lead Independent DirectorRoyalty Pharma plc announced that the independent directors of the Board have unanimously appointed Dr. Ted W. Love, an independent director since 2020, as Lead Independent Director. Dr. Love will continue to Chair the Nominating and Corporate Governance Committee. About Ted W. Love, MD: Dr. Love serves as BIO’s Immediate Past Chair of its Board of Directors following a two-year term as Chairman (2023-2025). Previously, he served as President and CEO of Global Blood Therapeutics (GBT) as well as a member of its board. Before GBT, he was EVP, Research and Development and Technical Operations, at Onyx Pharmaceuticals. Prior to Onyx, Ted served as President, CEO and Chairman of Nuvelo. Earlier in his career, Ted served as SVP, Development, at Theravance and held a number of senior management positions in medical affairs and product development at Genentech, including as Chairman of Genentech’s Product Development Committee and VP, Product Development. Dr. Love serves on the Board of Directors of Gilead Sciences and Structure Therapeutics. Ted holds an MD from Yale Medical School and a BA in molecular biology from Haverford College. He completed a residency in internal medicine and a fellowship in cardiology at the Massachusetts General Hospital.お知らせ • Aug 14Royalty Pharma plc Announces Stepdown of Henry Fernandez as Its Lead Independent Director, Effective August 13, 2025Royalty Pharma plc announced that Henry Fernandez, its Lead Independent Director, has stepped down from its Board of Directors, effective August 13, 2025. Mr. Fernandez joined the Royalty Pharma Board of Directors in July 2020 and was unanimously appointed as Lead Independent Director in March 2021. The company intends to name a new Lead Independent Director in the near future.お知らせ • Jul 18Royalty Pharma plc Declares Dividend on Class A Ordinary Share for Third Quarter of 2025, Payable on September 10, 2025The board of directors of Royalty Pharma plc has approved the payment of a dividend for the third quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid on September 10, 2025, to shareholders of record at the close of business on August 15, 2025.お知らせ • Jul 17+ 1 more updateRoyalty Pharma plc Appoints Carole Ho and Elizabeth Weatherman to the Board of Directors, Effective July 17, 2025Royalty Pharma plc announced the appointment of Carole Ho and Elizabeth (Bess) Weatherman to its Board of Directors, effective July 17, 2025 . Carole Ho is Chief Medical Officer and Head of Development at Denali Therapeutics, a biopharmaceutical company focused on neurodegenerative diseases. Bess Weatherman is a Special Limited Partner of Warburg Pincus LLC, a leading global private equity firm focused on growth investing. Carole Ho has 20 years of experience in biopharma. She currently serves as Chief Medical Officer and Head of Development at Denali Therapeutics, where she heads therapeutic development from early-stage planning to late-stage development in rare disease and neurology. Since 2018, she has also served on non-profit, private and public boards. Prior to Denali, she was Vice President of Clinical Development at Genentech, where she led development of therapeutics in neurology, immunology, ophthalmology and infectious disease. Carole received a SB in biochemistry, magna cum laude, from Harvard University and earned her MD, with honors in research, from Weill Cornell Medicine. Bess Weatherman is a seasoned investor of 35 years across the healthcare industry. She currently serves as a Special Limited Partner at Warburg Pincus, which she joined in 1988. During her tenure, she held the role of Partner, was a member of the Executive Management Group and led the firm’s Healthcare Group. She has served on the boards of numerous public and private companies and brings a deep understanding of capital markets, corporate governance, and medical innovation. Bess received a BA in English, summa cum laude and Phi Beta Kappa, from Mount Holyoke College and earned her MBA from the Stanford Graduate School of Business.お知らせ • Jun 30+ 1 more updateRoyalty Pharma plc(NasdaqGS:RPRX) dropped from Russell 1000 Value-Defensive IndexRoyalty Pharma plc(NasdaqGS:RPRX) dropped from Russell 1000 Value-Defensive Indexお知らせ • Apr 22Royalty Pharma plc Declares Second Quarter 2025 Dividend on A Ordinary Share, Payable on June 10, 2025The board of directors of Royalty Pharma plc has approved the payment of a dividend for the second quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid on June 10, 2025, to shareholders of record at the close of business on May 16, 2025.お知らせ • Apr 18Royalty Pharma plc to Report Q1, 2025 Results on May 08, 2025Royalty Pharma plc announced that they will report Q1, 2025 results Pre-Market on May 08, 2025お知らせ • Apr 14Royalty Pharma plc, Annual General Meeting, May 12, 2025Royalty Pharma plc, Annual General Meeting, May 12, 2025. Location: 110 east 59th street, new york 10022, new york United Statesお知らせ • Apr 09Royalty Pharma plc Appoints Vlad Coric, M.D. to Its Board of DirectorsRoyalty Pharma plc announced the appointment of Vlad Coric, M.D. to the company’s Board of Directors, effective immediately. Vlad Coric is the Chairman and Chief Executive Officer of Biohaven, a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas including neuroscience, immunology and oncology. Dr. Coric successfully led Biohaven through the FDA approval and launch of Nurtec ODT for the treatment of migraine. Under his leadership, the company also filed an NDA for its second drug candidate, zavegepant, as the first intranasal CGRP antagonist for ultra-rapid relief of migraine. During his tenure, Dr. Coric oversaw Biohaven’s impressive growth from its founding through its sale to Pfizer in May of 2022 for approximately $13 billion in total consideration.Dr. Coric has more than 20 years of drug discovery and clinical development experience at Yale School of Medicine and Bristol-Myers Squibb prior to leading Biohaven. Within the pharmaceutical industry, Dr. Coric has expertise working across therapeutic areas including neurology, psychiatry, immunology, virology, oncology and immuno-oncology. During his career, he has been involved in multiple drug development programs. Dr. Coric completed his postdoctoral internship, residency and fellowship at Yale School of Medicine, earned his medical degree from Wake Forest University School of Medicine and was an honors scholar in neurobiology and physiology at the University of Connecticut, where he received his Bachelor of Science degree.お知らせ • Jan 29Royalty Pharma plc to Report Q4, 2024 Results on Feb 11, 2025Royalty Pharma plc announced that they will report Q4, 2024 results Pre-Market on Feb 11, 2025お知らせ • Jan 13Royalty Pharma plc (NasdaqGS:RPRX) announces an Equity Buyback for $3,000 million worth of its shares.Royalty Pharma plc (NasdaqGS:RPRX) announces a share repurchase program. Under the program, the company will repurchase up to $3,000 million worth of its shares. The shares will be repurchased as part of the company’s evolving approach to returning capital to shareholders.お知らせ • Jan 10Royalty Pharma plc Declares Dividend for the First Quarter of 2025, Payable on March 10, 2025Royalty Pharma plc announced that its board of directors has declared a dividend for the first quarter of 2025 of $0.22 per Class A ordinary share, reflecting a 5% increase in the company’s quarterly dividend over the previous quarter’s dividend. The dividend will be paid on March 10, 2025 to shareholders of record at the close of business on February 21, 2025.Upcoming Dividend • Nov 08Upcoming dividend of US$0.21 per shareEligible shareholders must have bought the stock before 15 November 2024. Payment date: 10 December 2024. Payout ratio is a comfortable 32% but the company is not cash flow positive. Trailing yield: 3.2%. Lower than top quartile of German dividend payers (4.8%). Higher than average of industry peers (1.2%).Reported Earnings • Nov 07Third quarter 2024 earnings released: EPS: US$0.92 (vs US$0.16 in 3Q 2023)Third quarter 2024 results: EPS: US$0.92 (up from US$0.16 in 3Q 2023). Revenue: US$565.0m (up 5.3% from 3Q 2023). Net income: US$544.0m (up US$471.9m from 3Q 2023). Profit margin: 96% (up from 13% in 3Q 2023). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.Declared Dividend • Oct 21Second quarter dividend of US$0.21 announcedShareholders will receive a dividend of US$0.21. Ex-date: 15th November 2024 Payment date: 10th December 2024 Dividend yield will be 3.1%, which is higher than the industry average of 2.4%. Sustainability & Growth Dividend is covered by earnings (55% earnings payout ratio) but not covered by cash flows (124% cash payout ratio). The dividend has increased by an average of 8.8% per year over the past 4 years and payments have been stable during that time. EPS is expected to grow by 41% over the next 3 years, which should provide support to the dividend and adequate earnings cover.お知らせ • Oct 17Royalty Pharma plc to Report Q3, 2024 Results on Nov 06, 2024Royalty Pharma plc announced that they will report Q3, 2024 results Pre-Market on Nov 06, 2024お知らせ • Oct 11Royalty Pharma Declares Fourth Quarter 2024 Dividend, Payable on December 10, 2024Royalty Pharma plc has approved the payment of a dividend for the fourth quarter of 2024 of $0.21 per Class A ordinary share. The dividend will be paid on December 10, 2024, to shareholders of record at the close of business on November 15, 2024.Upcoming Dividend • Aug 09Upcoming dividend of US$0.21 per shareEligible shareholders must have bought the stock before 16 August 2024. Payment date: 13 September 2024. Payout ratio is a comfortable 55% and the cash payout ratio is 92%. Trailing yield: 3.2%. Lower than top quartile of German dividend payers (4.9%). Higher than average of industry peers (1.1%).お知らせ • Jul 24Royalty Pharma plc Appoints Molly Sawaya as Executive Vice President, Head of Human CapitalRoyalty Pharma plc announced the appointment of Molly Sawaya as Executive Vice President, Head of Human Capital. Molly joins Royalty Pharma from Hudson Bay Capital, where she was a Managing Director and Head of Colleague Experience, responsible for designing and delivering the firm’s Human Resources (HR) agenda, including onboarding, colleague engagement, professional development, compensation and benefits. Previously, Molly held a number of global HR roles of increasing responsibility at QBE Insurance Group, Perpetual Limited and National Australia Bank. Molly received her Bachelor of Arts and Master of Applied Science degrees in Psychology from the University of Sydney.Declared Dividend • Jul 22First quarter dividend of US$0.21 announcedShareholders will receive a dividend of US$0.21. Ex-date: 16th August 2024 Payment date: 13th September 2024 Dividend yield will be 3.1%, which is higher than the industry average of 2.4%. Sustainability & Growth Dividend is well covered by both earnings (45% earnings payout ratio) and cash flows (49% cash payout ratio). The dividend has increased by an average of 8.8% per year over the past 4 years and payments have been stable during that time. EPS is expected to grow by 45% over the next 3 years, which should provide support to the dividend and adequate earnings cover.お知らせ • Jul 20Royalty Pharma plc to Report Q2, 2024 Results on Aug 08, 2024Royalty Pharma plc announced that they will report Q2, 2024 results Pre-Market on Aug 08, 2024お知らせ • Jul 18Royalty Pharma plc Declares Dividend for the Third Quarter of 2024, Payable on September 13, 2024Royalty Pharma plc has approved the payment of a dividend for the third quarter of 2024 of $0.21 per Class A ordinary share. The dividend will be paid on September 13, 2024, to shareholders of record at the close of business on August 16, 2024.お知らせ • Jun 19Royalty Pharma plc Announces the Resignation of Rory Balfour Riggs as DirectorRoyalty Pharma plc announced the resignation of Rory Balfour Riggs as director with effect from 6 June 2024.お知らせ • Jun 18Royalty Pharma plc Announces Resignation of Mario Germano Giuliani as DirectorRoyalty Pharma plc announced resignation of Mario Germano Giuliani as director with effect from 6 June 2024.Reported Earnings • May 09First quarter 2024 earnings released: EPS: US$0.011 (vs US$0.77 in 1Q 2023)First quarter 2024 results: EPS: US$0.011 (down from US$0.77 in 1Q 2023). Revenue: US$568.0m (down 17% from 1Q 2023). Net income: US$5.00m (down 99% from 1Q 2023). Profit margin: 0.9% (down from 50% in 1Q 2023). Revenue is forecast to grow 8.3% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany.お知らせ • Apr 28Royalty Pharma plc, Annual General Meeting, Jun 06, 2024Royalty Pharma plc, Annual General Meeting, Jun 06, 2024, at 09:00 Eastern Daylight. Location: 110 East 59 th Street New York New York United States Agenda: To consider election of each of the eight director nominees listed in the accompanying Proxy Statement by separate ordinary resolutions; to approve on a non-binding advisory basis the compensation of named executive officers; to ratify on a non-binding advisory basis the appointment of Ernst & Young LLP, as independent registered public accounting firm; to approve receipt of our U.K. Annual Report and Accounts for the fiscal year ended December 31, 2023; and to consider other matters.Declared Dividend • Apr 23Fourth quarter dividend of US$0.21 announcedShareholders will receive a dividend of US$0.21. Ex-date: 16th May 2024 Payment date: 14th June 2024 Dividend yield will be 3.0%, which is higher than the industry average of 2.4%. Sustainability & Growth Dividend is covered by both earnings (32% earnings payout ratio) and cash flows (58% cash payout ratio). The dividend has increased by an average of 8.8% per year over the past 4 years and payments have been stable during that time. EPS is expected to grow by 22% over the next 3 years, which should provide support to the dividend and adequate earnings cover.お知らせ • Apr 17Royalty Pharma plc Declares Dividend for the Second Quarter of 2024, Payable on June 14, 2024The board of directors of Royalty Pharma plc has approved the payment of a dividend for the second quarter of 2024 of $0.21 per Class A ordinary share. The dividend will be paid on June 14, 2024, to shareholders of record at the close of business on May 17, 2024.お知らせ • Apr 04Royalty Pharma plc to Report Q1, 2024 Results on May 09, 2024Royalty Pharma plc announced that they will report Q1, 2024 results on May 09, 2024Reported Earnings • Feb 16Full year 2023 earnings released: EPS: US$2.54 (vs US$0.098 in FY 2022)Full year 2023 results: EPS: US$2.54 (up from US$0.098 in FY 2022). Revenue: US$2.35b (up 5.2% from FY 2022). Net income: US$1.13b (up US$1.09b from FY 2022). Profit margin: 48% (up from 1.9% in FY 2022). Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Pharmaceuticals industry in Germany.Upcoming Dividend • Feb 08Upcoming dividend of US$0.21 per share at 2.9% yieldEligible shareholders must have bought the stock before 15 February 2024. Payment date: 15 March 2024. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 2.9%. Lower than top quartile of German dividend payers (5.2%). Higher than average of industry peers (2.6%).お知らせ • Feb 07Novartis data42 AG entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG (XTRA:MOR) for €2.3 billion.Novartis data42 AG entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG (XTRA:MOR) for €2.3 billion on February 5, 2024. Under the agreed transaction, €68 per share will be paid. The agreement is unanimously approved by the Board of Directors of both companies. The transaction is subject to customary closing conditions, including acceptance of the takeover offer by at least 65% of MorphoSys AG’s outstanding shares and receipt of regulatory approvals and is expected to close in the first half of 2024. Centerview Partners is acting as lead financial advisor and Graham Robinson, Faiz Ahmad, Brian V. Breheny, Timothy F. Nelson, Maria Raptis, Resa K. Schlossberg, Jan Bauer, Matthias Horbach, Stephan Hutter and Caspar Schmelzer of Skadden, Arps, Slate, Meagher & Flom LLP acted as legal advisor to MorphoSys AG. Jenny Hochenberg, of Freshfields Bruckhaus Deringer US LLP acted as legal advisor to Novartis AG.お知らせ • Jan 31Royalty Pharma plc to Report Q4, 2023 Results on Feb 15, 2024Royalty Pharma plc announced that they will report Q4, 2023 results Pre-Market on Feb 15, 2024Declared Dividend • Jan 29Third quarter dividend of US$0.21 announcedShareholders will receive a dividend of US$0.21. Ex-date: 15th February 2024 Payment date: 15th March 2024 Dividend yield will be 2.9%, which is higher than the industry average of 2.3%. Sustainability & Growth Dividend is not covered by earnings (191% earnings payout ratio). However, it is well covered by cash flows (35% cash payout ratio). The dividend has increased by an average of 12% per year over the past 3 years and payments have been stable during that time. The company's earnings per share (EPS) would need to grow by 113% to bring the payout ratio under control. EPS is expected to grow by 104% over the next 3 years, which means the dividend may need to be reduced to reach a sustainable payout ratio.お知らせ • Jan 19Royalty Pharma plc Declares Dividend for the First Quarter of 2024, Payable on March 15, 2024Royalty Pharma plc announced that its board of directors has declared a dividend for the first quarter of 2024 of $0.21 per Class A share, reflecting a 5% increase in the company’s quarterly dividend over the previous quarter’s dividend. The dividend will be paid on March 15, 2024 to shareholders of record at the close of business on February 16, 2024.Recent Insider Transactions • Jan 01Director recently sold €6.4m worth of stockOn the 28th of December, Mario Giuliani sold around 252k shares on-market at roughly €25.43 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €18m. Insiders have been net sellers, collectively disposing of €26m more than they bought in the last 12 months.Recent Insider Transactions • Dec 18Director recently sold €18m worth of stockOn the 14th of December, Mario Giuliani sold around 672k shares on-market at roughly €26.31 per share. This transaction amounted to 2.0% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €19m more than they bought in the last 12 months.Reported Earnings • Nov 09Third quarter 2023 earnings released: EPS: US$0.16 (vs US$0.33 in 3Q 2022)Third quarter 2023 results: EPS: US$0.16 (down from US$0.33 in 3Q 2022). Revenue: US$536.3m (down 6.5% from 3Q 2022). Net income: US$72.1m (down 49% from 3Q 2022). Profit margin: 13% (down from 25% in 3Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 3.0% growth forecast for the Pharmaceuticals industry in Germany.Upcoming Dividend • Nov 09Upcoming dividend of US$0.20 per share at 2.9% yieldEligible shareholders must have bought the stock before 16 November 2023. Payment date: 15 December 2023. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 2.9%. Lower than top quartile of German dividend payers (5.1%). Higher than average of industry peers (2.6%).お知らせ • Sep 22Royalty Pharma Appoints Eric Schneider as Chief Technology OfficerRoyalty Pharma plc announced the appointment of Eric Schneider as Senior Vice President, Chief Technology Officer. Eric will also join Royalty Pharma’s Senior Leadership Committee. Eric joins Royalty Pharma from Verisk, a global leader in data-driven analytic insights and solutions, where he was a Senior Vice President, Chief Data Officer and Chief Technology Officer, and a member of the Executive Leadership Team. During his tenure at Verisk, he led their migration to the cloud, mainframe modernization strategy and Data Governance and Data Strategy Team. Prior to Verisk, Mr. Schneider held senior IT leadership roles at Moody’s Investor Services, Barclay’s Capital, AIG and McKinsey & Company.Recent Insider Transactions • Aug 14Executive VP & CFO recently sold €2.1m worth of stockOn the 10th of August, Terrance Coyne sold around 75k shares on-market at roughly €27.90 per share. This transaction amounted to 8.2% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €6.1m. Terrance has been a net seller over the last 12 months, reducing personal holdings by €4.2m.Upcoming Dividend • Aug 10Upcoming dividend of US$0.20 per share at 2.6% yieldEligible shareholders must have bought the stock before 17 August 2023. Payment date: 15 September 2023. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 2.6%. Lower than top quartile of German dividend payers (4.7%). In line with average of industry peers (2.5%).Reported Earnings • Aug 09Second quarter 2023 earnings released: EPS: US$0.51 (vs US$0.70 in 2Q 2022)Second quarter 2023 results: EPS: US$0.51 (down from US$0.70 in 2Q 2022). Revenue: US$538.0m (flat on 2Q 2022). Net income: US$228.0m (down 25% from 2Q 2022). Profit margin: 42% (down from 57% in 2Q 2022). Revenue is forecast to grow 7.9% p.a. on average during the next 3 years, compared to a 2.9% growth forecast for the Pharmaceuticals industry in Germany.Board Change • Aug 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. 1 highly experienced director. Independent Director Dave Hodgson was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jul 18Royalty Pharma plc Declares Dividend on Class A Ordinary Shares for the Third Quarter of 2023, Payable on September 15, 2023The board of directors of Royalty Pharma plc has approved the payment of a dividend for the third quarter of 2023 of $0.20 per Class A ordinary share. The dividend will be paid on September 15, 2023, to shareholders of record at the close of business on August 18, 2023.Recent Insider Transactions • Jul 17Executive VP & CFO recently sold €2.1m worth of stockOn the 13th of July, Terrance Coyne sold around 75k shares on-market at roughly €27.70 per share. This transaction amounted to 6.3% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €6.1m. This was Terrance's only on-market trade for the last 12 months.Recent Insider Transactions • Jun 30Founder recently bought €3.5m worth of stockOn the 28th of June, Pablo Legorreta bought around 130k shares on-market at roughly €27.04 per share. This transaction amounted to 3.6% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth €7.1m. Pablo has been a buyer over the last 12 months, purchasing a net total of €18m worth in shares.お知らせ • Jun 30Royalty Pharma plc to Report Q2, 2023 Results on Aug 08, 2023Royalty Pharma plc announced that they will report Q2, 2023 results on Aug 08, 2023Recent Insider Transactions • Jun 11Insider recently sold €6.1m worth of stockOn the 6th of June, George Lloyd sold around 192k shares on-market at roughly €31.53 per share. This transaction amounted to 17% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €191m more than they bought in the last 12 months.Recent Insider Transactions • May 21Founder recently bought €7.1m worth of stockOn the 17th of May, Pablo Legorreta bought around 230k shares on-market at roughly €30.83 per share. This transaction amounted to 7.3% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Pablo's only on-market trade for the last 12 months.Upcoming Dividend • May 11Upcoming dividend of US$0.20 per share at 2.4% yieldEligible shareholders must have bought the stock before 18 May 2023. Payment date: 15 June 2023. Payout ratio and cash payout ratio are on the higher end at 76% and 91% respectively. Trailing yield: 2.4%. Lower than top quartile of German dividend payers (4.6%). In line with average of industry peers (2.5%).Reported Earnings • May 09First quarter 2023 earnings released: EPS: US$0.77 (vs US$0.12 in 1Q 2022)First quarter 2023 results: EPS: US$0.77 (up from US$0.12 in 1Q 2022). Revenue: US$684.0m (up 22% from 1Q 2022). Net income: US$341.0m (up US$289.2m from 1Q 2022). Profit margin: 50% (up from 9.2% in 1Q 2022). Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany.Recent Insider Transactions • Apr 02Director recently sold €4.7m worth of stockOn the 30th of March, Rory Riggs sold around 140k shares on-market at roughly €33.29 per share. This transaction amounted to 8.7% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €219m more than they bought in the last 12 months.Recent Insider Transactions • Mar 02Insider recently sold €879k worth of stockOn the 23rd of February, George Lloyd sold around 25k shares on-market at roughly €35.18 per share. This transaction amounted to 2.0% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €3.5m. Insiders have been net sellers, collectively disposing of €212m more than they bought in the last 12 months.Reported Earnings • Feb 16Full year 2022 earnings released: EPS: US$0.097 (vs US$1.49 in FY 2021)Full year 2022 results: EPS: US$0.097 (down from US$1.49 in FY 2021). Revenue: US$2.24b (down 2.3% from FY 2021). Net income: US$43.0m (down 93% from FY 2021). Profit margin: 1.9% (down from 27% in FY 2021). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Pharmaceuticals industry in Germany.Upcoming Dividend • Feb 08Upcoming dividend of US$0.20 per share at 2.1% yieldEligible shareholders must have bought the stock before 15 February 2023. Payment date: 15 March 2023. Payout ratio is a comfortable 64% and the cash payout ratio is 81%. Trailing yield: 2.1%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (2.6%).お知らせ • Jan 16Royalty Pharma plc to Report Q4, 2022 Results on Feb 15, 2023Royalty Pharma plc announced that they will report Q4, 2022 results on Feb 15, 2023お知らせ • Jan 10Royalty Pharma Declares First Quarter 2023 Dividend, Payable on March 15, 2023Royalty Pharma plc declared a dividend for the first quarter of 2023 of $0.20 per Class A share, reflecting a 5.3% increase in the company's quarterly dividend over the previous quarter's dividend. The dividend will be paid on March 15, 2023 to shareholders of record at the close of business on February 16, 2023.お知らせ • Dec 17Royalty Pharma Announces Expansion of Senior Leadership TeamRoyalty Pharma plc announced the expansion of its senior leadership team. This expansion highlights Royalty Pharma’s success in developing a talented, diverse and experienced leadership team responsible for formulating and executing on its mission to accelerate innovation and transform patient lives. The following promotions are effective January 1, 2023, and each individual will join the Senior Leadership Committee: Sara Klymkowskywill be promoted to Senior Vice President, Research & Investments. Sara has been an integral member of the Research & Investments team since joining Royalty Pharma in 2012. She has played a key role in executing many of Royalty Pharma’s most important transactions, including investments in the Vertex cystic fibrosis franchise, Tysabri and Trelegy. Brienne Kugler will be promoted to Senior Vice President, Research & Investments. Brienne has been a key member of the Research & Investments team since joining Royalty Pharma in 2014. She has played a major role in executing many of Royalty Pharma’s most important transactions, including multiple Biohaven investments, Tremfya and Evrysdi. Alessandra Sassun will be promoted to Senior Vice President, Head of Human Capital. Alessandra joined Royalty Pharma in 2020 and is responsible for overseeing Royalty Pharma’s human resource planning, professional development and performance management.Recent Insider Transactions • Dec 16Director recently sold €2.4m worth of stockOn the 12th of December, Rory Riggs sold around 60k shares on-market at roughly €39.91 per share. This transaction amounted to 35% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €33m. Insiders have been net sellers, collectively disposing of €213m more than they bought in the last 12 months.Recent Insider Transactions • Dec 07Director recently sold €15m worth of stockOn the 2nd of December, Mario Giuliani sold around 363k shares on-market at roughly €42.00 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €43m. Insiders have been net sellers, collectively disposing of €207m more than they bought in the last 12 months.Board Change • Nov 16High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. 1 highly experienced director. Founder, Chairman of the Board & CEO Pablo Legorreta is the most experienced director on the board, commencing their role in 1996. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Upcoming Dividend • Nov 10Upcoming dividend of US$0.19 per shareEligible shareholders must have bought the stock before 17 November 2022. Payment date: 15 December 2022. Payout ratio is a comfortable 64% and the cash payout ratio is 81%. Trailing yield: 1.8%. Lower than top quartile of German dividend payers (5.0%). Lower than average of industry peers (2.7%).Reported Earnings • Nov 09Third quarter 2022 earnings released: EPS: US$0.33 (vs US$0.24 in 3Q 2021)Third quarter 2022 results: EPS: US$0.33 (up from US$0.24 in 3Q 2021). Revenue: US$573.5m (down 2.1% from 3Q 2021). Net income: US$142.7m (up 40% from 3Q 2021). Profit margin: 25% (up from 17% in 3Q 2021). The increase in margin was driven by lower expenses. Revenue is forecast to grow 8.4% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Pharmaceuticals industry in Germany.お知らせ • Oct 18Royalty Pharma Declares Fourth Quarter 2022 Dividend, Payable on December 15, 2022Royalty Pharma plc has approved the payment of a dividend for the fourth quarter of 2022 of $0.19 per Class A ordinary share. The dividend will be paid on December 15, 2022, to shareholders of record at the close of business on November 18, 2022.お知らせ • Oct 13Royalty Pharma plc Announces Executive ChangesRoyalty Pharma plc announced an expansion of its leadership team. Art McGivern has joined Royalty Pharma as Executive Vice President, Investments & General Counsel and George Lloyd has been promoted to Executive Vice President, Investments & Chief Legal Officer. Art McGivern joins Royalty Pharma from Goodwin Procter where he was a partner in its Life Sciences Group. He has been Royalty Pharma's lead outside lawyer on substantially all investment transactions since 2012. Art brings experience across public and private securities offerings, mergers and acquisitions, royalty-based financings and other complex transactions, and has advised companies in their ongoing corporate matters. Art has a BSCE from Tufts University and a JD from Boston University.George Lloyd leads the legal and compliance functions at Royalty Pharma. He joined Royalty Pharma in 2011 after representing Royalty Pharma on all transactional work since 2006. George was previously a partner in Goodwin Procter'sPrivate Equity Group. He has an AB from Princeton University and a JD from New York University Law School.お知らせ • Oct 05Royalty Pharma plc to Report Q3, 2022 Results on Nov 08, 2022Royalty Pharma plc announced that they will report Q3, 2022 results at 9:30 AM, US Eastern Standard Time on Nov 08, 2022Recent Insider Transactions • Sep 11Director recently sold €43m worth of stockOn the 8th of September, Mario Giuliani sold around 998k shares on-market at roughly €42.83 per share. This transaction amounted to 1.7% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €85m more than they bought in the last 12 months.Recent Insider Transactions • Aug 13Director recently sold €1.9m worth of stockOn the 9th of August, Rory Riggs sold around 45k shares on-market at roughly €42.75 per share. In the last 3 months, they made an even bigger sale worth €5.6m. Insiders have been net sellers, collectively disposing of €43m more than they bought in the last 12 months.Upcoming Dividend • Aug 11Upcoming dividend of US$0.19 per shareEligible shareholders must have bought the stock before 18 August 2022. Payment date: 15 September 2022. Payout ratio is a comfortable 67% and the cash payout ratio is 100%. Trailing yield: 1.7%. Lower than top quartile of German dividend payers (4.5%). Lower than average of industry peers (2.7%).Reported Earnings • Aug 05Second quarter 2022 earnings released: EPS: US$0.70 (vs US$1.08 in 2Q 2021)Second quarter 2022 results: EPS: US$0.70 (down from US$1.08 in 2Q 2021). Revenue: US$536.0m (down 3.4% from 2Q 2021). Net income: US$305.0m (down 31% from 2Q 2021). Profit margin: 57% (down from 79% in 2Q 2021). The decrease in margin was primarily driven by higher expenses. Over the next year, revenue is forecast to grow 5.3%, compared to a 8.0% growth forecast for the industry in Germany.お知らせ • Jul 16Royalty Pharma plc Declares Third Quarter 2022 Dividend, to Be Paid on September 15, 2022The board of directors of Royalty Pharma plc has approved the payment of a dividend for the third quarter of 2022 of $0.19 per Class A ordinary share. The dividend will be paid on September 15, 2022, to shareholders of record at the close of business on August 19, 2022.お知らせ • Jul 02Royalty Pharma plc to Report Q2, 2022 Results on Aug 04, 2022Royalty Pharma plc announced that they will report Q2, 2022 results at 9:30 AM, US Eastern Standard Time on Aug 04, 2022Recent Insider Transactions • Jul 01Director recently sold €1.2m worth of stockOn the 29th of June, Rory Riggs sold around 30k shares on-market at roughly €40.28 per share. In the last 3 months, they made an even bigger sale worth €5.6m. Insiders have been net sellers, collectively disposing of €41m more than they bought in the last 12 months.お知らせ • Jun 25Royalty Pharma plc Announces Directorate ChangeRoyalty Pharma plc announced the resignation of William Edward Ford and appointment of David Hodgson with effect from 23 June 2022.Recent Insider Transactions • Jun 12Insider recently sold €3.9m worth of stockOn the 8th of June, James Reddoch sold around 100k shares on-market at roughly €38.70 per share. In the last 3 months, there was an even bigger sale from another insider worth €5.6m. Insiders have been net sellers, collectively disposing of €40m more than they bought in the last 12 months.Recent Insider Transactions • May 25Director recently sold €5.6m worth of stockOn the 20th of May, Rory Riggs sold around 150k shares on-market at roughly €37.37 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €43m more than they bought in the last 12 months.Upcoming Dividend • May 12Upcoming dividend of US$0.19 per shareEligible shareholders must have bought the stock before 19 May 2022. Payment date: 15 June 2022. Payout ratio is a comfortable 49% but the company is paying out more than the cash it is generating. Trailing yield: 2.0%. Lower than top quartile of German dividend payers (4.2%). Lower than average of industry peers (2.7%).Reported Earnings • May 06First quarter 2022 earnings released: EPS: US$0.12 (vs US$0.18 in 1Q 2021)First quarter 2022 results: EPS: US$0.12 (down from US$0.18 in 1Q 2021). Revenue: US$563.0m (down 1.7% from 1Q 2021). Net income: US$52.0m (down 25% from 1Q 2021). Profit margin: 9.2% (down from 12% in 1Q 2021). The decrease in margin was primarily driven by lower revenue. Over the next year, revenue is forecast to grow 1.1%, compared to a 8.1% growth forecast for the industry in Germany.Board Change • Apr 27High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. 1 highly experienced director. Founder, Chairman of the Board & CEO Pablo Legorreta is the most experienced director on the board, commencing their role in 1996. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Apr 19Royalty Pharma plc Declares Second Quarter 2022 Dividend, Payable on June 15, 2022The board of directors of Royalty Pharma plc has approved the payment of a dividend for the second quarter of 2022 of $0.19 per Class A ordinary share. The dividend will be paid on June 15, 2022, to shareholders of record at the close of business on May 20, 2022.お知らせ • Apr 04Royalty Pharma plc to Report Q1, 2022 Results on May 05, 2022Royalty Pharma plc announced that they will report Q1, 2022 results on May 05, 2022株主還元RPDDE PharmaceuticalsDE 市場7D0.9%-1.5%-0.7%1Y58.6%21.7%2.0%株主還元を見る業界別リターン: RPD過去 1 年間で21.7 % の収益を上げたGerman Pharmaceuticals業界を上回りました。リターン対市場: RPD過去 1 年間で2 % の収益を上げたGerman市場を上回りました。価格変動Is RPD's price volatile compared to industry and market?RPD volatilityRPD Average Weekly Movement4.2%Pharmaceuticals Industry Average Movement6.0%Market Average Movement5.9%10% most volatile stocks in DE Market13.0%10% least volatile stocks in DE Market2.8%安定した株価: RPD 、 German市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: RPDの 週次ボラティリティ ( 4% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト1996100Pablo Legorretawww.royaltypharma.comロイヤリティ・ファーマは、バイオ医薬品ロイヤリティの買い手であり、米国のバイオ医薬品業界におけるイノベーションの資金提供者でもある。同社のポートフォリオは、希少疾患、癌、神経科学、感染症、血液学、糖尿病など様々な治療分野に対応する約35の上市済み治療薬と14の開発段階製品候補のロイヤルティで構成されている。同社は1996年に設立され、ニューヨーク州ニューヨークに本社を置いている。もっと見るRoyalty Pharma plc 基礎のまとめRoyalty Pharma の収益と売上を時価総額と比較するとどうか。RPD 基礎統計学時価総額€27.31b収益（TTM）€714.16m売上高(TTM)€2.11b29.4xPER（株価収益率10.0xP/SレシオRPD は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計RPD 損益計算書（TTM）収益US$2.44b売上原価-US$366.18m売上総利益US$2.81bその他の費用US$1.98b収益US$826.29m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）1.86グロス・マージン115.00%純利益率33.86%有利子負債／自己資本比率90.1%RPD の長期的なパフォーマンスは？過去の実績と比較を見る配当金1.7%現在の配当利回り47%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/14 03:39終値2026/06/12 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Royalty Pharma plc 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。14 アナリスト機関Jason Matthew GerberryBofA Global ResearchGeoffrey MeachamCitigroup IncPrem ChulakiCrispIdea11 その他のアナリストを表示
お知らせ • Jun 10Royalty Pharma plc Announces Resignation of Errol Bento Jose Trinidade De Souza as Director, Effective June 4, 2026Royalty Pharma Plc announced the resignation of Errol Bento Jose Trinidade De Souza as director of the company, with effect from June 4, 2026.
お知らせ • Apr 17Royalty Pharma plc Declares Dividend for the Second Quarter 2026, Payable on June 10, 2026Royalty Pharma plc approved the payment of a dividend for the second quarter of 2026 of $0.235 per Class A ordinary share. The dividend will be paid on June 10, 2026, to shareholders of record at the close of business on May 15, 2026.
お知らせ • Apr 16Royalty Pharma plc to Report Q1, 2026 Results on May 06, 2026Royalty Pharma plc announced that they will report Q1, 2026 results Pre-Market on May 06, 2026
お知らせ • Apr 13Royalty Pharma plc, Annual General Meeting, Jun 04, 2026Royalty Pharma plc, Annual General Meeting, Jun 04, 2026. Location: 110 east 59th street, ny 10022, new york United States
お知らせ • Mar 23Royalty Pharma plc Appoints Lucas Glass as Head of Artificial Intelligence, Effective April 2026Royalty Pharma plc announced the appointment of Lucas Glass as Head of Artificial Intelligence, effective April 2026. Lucas will lead the development and implementation of artificial intelligence capabilities across Royalty Pharma. Lucas most recently served as Senior Vice President of Technology at IQVIA, a global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, where he led enterprise architecture, domain architecture and platform engineering initiatives. Earlier in his career, Lucas held data science and statistical leadership roles at Routine Recovery and the U.S. Department of Justice. Lucas completed doctoral studies in statistics at Temple University, an MS in biostatistics from Drexel University and a BA in physics from Boston University.
お知らせ • Mar 18Royalty Pharma plc Announces Executive AppointmentsRoyalty Pharma plc announced that Greg Butz will join Royalty Pharma as Executive Vice President, Partnering & Investments, effective June 2026. Greg joins Royalty Pharma from Bank of America, where he was the Global Co-Head of Healthcare Investment Banking. At Bank of America, Greg worked with public and private biopharma companies across a range of capital raising and strategic advisory transactions. Prior to his acting as Global Co-Head of Healthcare, Greg held Co-Head North American Healthcare Investment Banking and Head of Life Sciences Investment Banking roles at Bank of America. Greg graduated with a BA from Williams College and received an MBA from Dartmouth. In connection with hiring Mr. Butz, Chris Hite has been appointed Chairman, Partnering & Investments where he will continue to expand Royalty Pharma’s global relationship network and play a central role in transactions. Chris is a highly valued partner whose leadership, insight, and dedication have been instrumental to the growth and evolution of Royalty Pharma, as well as to the advancement of the broader royalty market. The company announced recent expansion of its leadership team, including the addition of Ken Sun as new Head of Asia. Together, Greg and Ken working with Chris Hite will be highly complementary and will enhance ability to originate and execute differentiated royalty transactions worldwide.
お知らせ • Jun 10Royalty Pharma plc Announces Resignation of Errol Bento Jose Trinidade De Souza as Director, Effective June 4, 2026Royalty Pharma Plc announced the resignation of Errol Bento Jose Trinidade De Souza as director of the company, with effect from June 4, 2026.
お知らせ • Apr 17Royalty Pharma plc Declares Dividend for the Second Quarter 2026, Payable on June 10, 2026Royalty Pharma plc approved the payment of a dividend for the second quarter of 2026 of $0.235 per Class A ordinary share. The dividend will be paid on June 10, 2026, to shareholders of record at the close of business on May 15, 2026.
お知らせ • Apr 16Royalty Pharma plc to Report Q1, 2026 Results on May 06, 2026Royalty Pharma plc announced that they will report Q1, 2026 results Pre-Market on May 06, 2026
お知らせ • Apr 13Royalty Pharma plc, Annual General Meeting, Jun 04, 2026Royalty Pharma plc, Annual General Meeting, Jun 04, 2026. Location: 110 east 59th street, ny 10022, new york United States
お知らせ • Mar 23Royalty Pharma plc Appoints Lucas Glass as Head of Artificial Intelligence, Effective April 2026Royalty Pharma plc announced the appointment of Lucas Glass as Head of Artificial Intelligence, effective April 2026. Lucas will lead the development and implementation of artificial intelligence capabilities across Royalty Pharma. Lucas most recently served as Senior Vice President of Technology at IQVIA, a global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, where he led enterprise architecture, domain architecture and platform engineering initiatives. Earlier in his career, Lucas held data science and statistical leadership roles at Routine Recovery and the U.S. Department of Justice. Lucas completed doctoral studies in statistics at Temple University, an MS in biostatistics from Drexel University and a BA in physics from Boston University.
お知らせ • Mar 18Royalty Pharma plc Announces Executive AppointmentsRoyalty Pharma plc announced that Greg Butz will join Royalty Pharma as Executive Vice President, Partnering & Investments, effective June 2026. Greg joins Royalty Pharma from Bank of America, where he was the Global Co-Head of Healthcare Investment Banking. At Bank of America, Greg worked with public and private biopharma companies across a range of capital raising and strategic advisory transactions. Prior to his acting as Global Co-Head of Healthcare, Greg held Co-Head North American Healthcare Investment Banking and Head of Life Sciences Investment Banking roles at Bank of America. Greg graduated with a BA from Williams College and received an MBA from Dartmouth. In connection with hiring Mr. Butz, Chris Hite has been appointed Chairman, Partnering & Investments where he will continue to expand Royalty Pharma’s global relationship network and play a central role in transactions. Chris is a highly valued partner whose leadership, insight, and dedication have been instrumental to the growth and evolution of Royalty Pharma, as well as to the advancement of the broader royalty market. The company announced recent expansion of its leadership team, including the addition of Ken Sun as new Head of Asia. Together, Greg and Ken working with Chris Hite will be highly complementary and will enhance ability to originate and execute differentiated royalty transactions worldwide.
お知らせ • Mar 03Royalty Pharma plc Appoints Kenneth Sun as Senior Vice President and Head of Asia, Effective May 2026Royalty Pharma plc announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. Ken will be based in Hong Kong and lead the company’s royalty business in Asia. Ken joins Royalty Pharma from Morgan Stanley, where he was Head of Asia Pacific Healthcare Investment Banking. Asia-based biotechnology companies are now prolific creators of innovative therapeutics. In 2025, the out-licensing of Chinese medicines alone comprised over $130 billion of announced transaction value, up from approximately $14 billion in 2021, as multinational pharmaceutical companies increasingly recognized the value of this innovation. This momentum is expected to continue into 2026 and beyond, as modalities, therapeutic areas and deal structures out of Asia become increasingly innovative, comprehensive and diverse. The royalties from these transactions are creating a new market opportunity for royalty-based funding. Royalty Pharma will partner with biotechnology innovators to build the royalty market in greater Asia, just as Royalty Pharma played a foundational role in establishing the biopharma royalty market in the west by working closely with universities, research institutions and biopharma companies over two decades ago. In his previous role as Managing Director, Head of Asia Pacific Healthcare Investment Banking at Morgan Stanley, Ken led the establishment of the bank’s leadership position in China. He advised a diverse spectrum of strategic clients, including biotech, medtech, CRO, pharmaceutical and healthcare service companies. Ken successfully led origination and execution of notable and industry defining healthcare transactions across IPOs, M&A, and biotech licensing advisory, with a primary focus on Greater China. He brings more than 18 years of investment banking experience, having previously worked at China Renaissance and BNP Paribas. Ken holds a Bachelor’s degree in Electrical Engineering from Queen’s University, Canada.
お知らせ • Feb 11Royalty Pharma plc Provides Earnings Guidance for the Full Year 2026Royalty Pharma plc provided earnings guidance for the full year 2026. For the period, the company expects 2026 Portfolio Receipts to be between $3,275 million and $3,425 million. Portfolio Receipts guidance represents expected growth of 14% to 16% in 2025. Royalty Pharma’s full year 2025 guidance reflects a negligible estimated foreign exchange impact to Portfolio Receipts, assuming current foreign exchange rates prevail for the rest of 2025.
お知らせ • Jan 21Royalty Pharma plc to Report Q4, 2025 Results on Feb 11, 2026Royalty Pharma plc announced that they will report Q4, 2025 results Pre-Market on Feb 11, 2026
お知らせ • Jan 09Royalty Pharma plc Declares Dividend on Class A Ordinary Share for the First Quarter of 2026, Payable on March 10, 2026Royalty Pharma plc announced that its board of directors has declared a dividend for the first quarter of 2026 of $0.235 per Class A ordinary share, reflecting a 6.8% increase in the company’s quarterly dividend over the previous quarter’s dividend. The dividend will be paid on March 10, 2026 to shareholders of record at the close of business on February 20, 2026.
お知らせ • Nov 06Royalty Pharma plc Announces Earnings Guidance for the Full Year 2025Royalty Pharma plc announced earnings guidance for the full year 2025. For the period, the company expects 2025 Portfolio Receipts to be between $3,200 million and $3,250 million (previously $3,050 million to $3,150 million), representing expected growth of 14% to 16% (previously 9% to 12%).
お知らせ • Oct 17Royalty Pharma plc Approves Dividend on Class A Ordinary Share for Fourth Quarter of 2025 , Payable on December 10, 2025The board of directors of Royalty Pharma plc approved the payment of a dividend for the fourth quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid on December 10, 2025, to shareholders of record at the close of business on November 14, 2025.
お知らせ • Oct 02Royalty Pharma plc to Report Q3, 2025 Results on Nov 05, 2025Royalty Pharma plc announced that they will report Q3, 2025 results Pre-Market on Nov 05, 2025
お知らせ • Sep 30Royalty Pharma plc Appoints Ted W. Love as Lead Independent DirectorRoyalty Pharma plc announced that the independent directors of the Board have unanimously appointed Dr. Ted W. Love, an independent director since 2020, as Lead Independent Director. Dr. Love will continue to Chair the Nominating and Corporate Governance Committee. About Ted W. Love, MD: Dr. Love serves as BIO’s Immediate Past Chair of its Board of Directors following a two-year term as Chairman (2023-2025). Previously, he served as President and CEO of Global Blood Therapeutics (GBT) as well as a member of its board. Before GBT, he was EVP, Research and Development and Technical Operations, at Onyx Pharmaceuticals. Prior to Onyx, Ted served as President, CEO and Chairman of Nuvelo. Earlier in his career, Ted served as SVP, Development, at Theravance and held a number of senior management positions in medical affairs and product development at Genentech, including as Chairman of Genentech’s Product Development Committee and VP, Product Development. Dr. Love serves on the Board of Directors of Gilead Sciences and Structure Therapeutics. Ted holds an MD from Yale Medical School and a BA in molecular biology from Haverford College. He completed a residency in internal medicine and a fellowship in cardiology at the Massachusetts General Hospital.
お知らせ • Aug 14Royalty Pharma plc Announces Stepdown of Henry Fernandez as Its Lead Independent Director, Effective August 13, 2025Royalty Pharma plc announced that Henry Fernandez, its Lead Independent Director, has stepped down from its Board of Directors, effective August 13, 2025. Mr. Fernandez joined the Royalty Pharma Board of Directors in July 2020 and was unanimously appointed as Lead Independent Director in March 2021. The company intends to name a new Lead Independent Director in the near future.
お知らせ • Jul 18Royalty Pharma plc Declares Dividend on Class A Ordinary Share for Third Quarter of 2025, Payable on September 10, 2025The board of directors of Royalty Pharma plc has approved the payment of a dividend for the third quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid on September 10, 2025, to shareholders of record at the close of business on August 15, 2025.
お知らせ • Jul 17+ 1 more updateRoyalty Pharma plc Appoints Carole Ho and Elizabeth Weatherman to the Board of Directors, Effective July 17, 2025Royalty Pharma plc announced the appointment of Carole Ho and Elizabeth (Bess) Weatherman to its Board of Directors, effective July 17, 2025 . Carole Ho is Chief Medical Officer and Head of Development at Denali Therapeutics, a biopharmaceutical company focused on neurodegenerative diseases. Bess Weatherman is a Special Limited Partner of Warburg Pincus LLC, a leading global private equity firm focused on growth investing. Carole Ho has 20 years of experience in biopharma. She currently serves as Chief Medical Officer and Head of Development at Denali Therapeutics, where she heads therapeutic development from early-stage planning to late-stage development in rare disease and neurology. Since 2018, she has also served on non-profit, private and public boards. Prior to Denali, she was Vice President of Clinical Development at Genentech, where she led development of therapeutics in neurology, immunology, ophthalmology and infectious disease. Carole received a SB in biochemistry, magna cum laude, from Harvard University and earned her MD, with honors in research, from Weill Cornell Medicine. Bess Weatherman is a seasoned investor of 35 years across the healthcare industry. She currently serves as a Special Limited Partner at Warburg Pincus, which she joined in 1988. During her tenure, she held the role of Partner, was a member of the Executive Management Group and led the firm’s Healthcare Group. She has served on the boards of numerous public and private companies and brings a deep understanding of capital markets, corporate governance, and medical innovation. Bess received a BA in English, summa cum laude and Phi Beta Kappa, from Mount Holyoke College and earned her MBA from the Stanford Graduate School of Business.
お知らせ • Jun 30+ 1 more updateRoyalty Pharma plc(NasdaqGS:RPRX) dropped from Russell 1000 Value-Defensive IndexRoyalty Pharma plc(NasdaqGS:RPRX) dropped from Russell 1000 Value-Defensive Index
お知らせ • Apr 22Royalty Pharma plc Declares Second Quarter 2025 Dividend on A Ordinary Share, Payable on June 10, 2025The board of directors of Royalty Pharma plc has approved the payment of a dividend for the second quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid on June 10, 2025, to shareholders of record at the close of business on May 16, 2025.
お知らせ • Apr 18Royalty Pharma plc to Report Q1, 2025 Results on May 08, 2025Royalty Pharma plc announced that they will report Q1, 2025 results Pre-Market on May 08, 2025
お知らせ • Apr 14Royalty Pharma plc, Annual General Meeting, May 12, 2025Royalty Pharma plc, Annual General Meeting, May 12, 2025. Location: 110 east 59th street, new york 10022, new york United States
お知らせ • Apr 09Royalty Pharma plc Appoints Vlad Coric, M.D. to Its Board of DirectorsRoyalty Pharma plc announced the appointment of Vlad Coric, M.D. to the company’s Board of Directors, effective immediately. Vlad Coric is the Chairman and Chief Executive Officer of Biohaven, a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas including neuroscience, immunology and oncology. Dr. Coric successfully led Biohaven through the FDA approval and launch of Nurtec ODT for the treatment of migraine. Under his leadership, the company also filed an NDA for its second drug candidate, zavegepant, as the first intranasal CGRP antagonist for ultra-rapid relief of migraine. During his tenure, Dr. Coric oversaw Biohaven’s impressive growth from its founding through its sale to Pfizer in May of 2022 for approximately $13 billion in total consideration.Dr. Coric has more than 20 years of drug discovery and clinical development experience at Yale School of Medicine and Bristol-Myers Squibb prior to leading Biohaven. Within the pharmaceutical industry, Dr. Coric has expertise working across therapeutic areas including neurology, psychiatry, immunology, virology, oncology and immuno-oncology. During his career, he has been involved in multiple drug development programs. Dr. Coric completed his postdoctoral internship, residency and fellowship at Yale School of Medicine, earned his medical degree from Wake Forest University School of Medicine and was an honors scholar in neurobiology and physiology at the University of Connecticut, where he received his Bachelor of Science degree.
お知らせ • Jan 29Royalty Pharma plc to Report Q4, 2024 Results on Feb 11, 2025Royalty Pharma plc announced that they will report Q4, 2024 results Pre-Market on Feb 11, 2025
お知らせ • Jan 13Royalty Pharma plc (NasdaqGS:RPRX) announces an Equity Buyback for $3,000 million worth of its shares.Royalty Pharma plc (NasdaqGS:RPRX) announces a share repurchase program. Under the program, the company will repurchase up to $3,000 million worth of its shares. The shares will be repurchased as part of the company’s evolving approach to returning capital to shareholders.
お知らせ • Jan 10Royalty Pharma plc Declares Dividend for the First Quarter of 2025, Payable on March 10, 2025Royalty Pharma plc announced that its board of directors has declared a dividend for the first quarter of 2025 of $0.22 per Class A ordinary share, reflecting a 5% increase in the company’s quarterly dividend over the previous quarter’s dividend. The dividend will be paid on March 10, 2025 to shareholders of record at the close of business on February 21, 2025.
Upcoming Dividend • Nov 08Upcoming dividend of US$0.21 per shareEligible shareholders must have bought the stock before 15 November 2024. Payment date: 10 December 2024. Payout ratio is a comfortable 32% but the company is not cash flow positive. Trailing yield: 3.2%. Lower than top quartile of German dividend payers (4.8%). Higher than average of industry peers (1.2%).
Reported Earnings • Nov 07Third quarter 2024 earnings released: EPS: US$0.92 (vs US$0.16 in 3Q 2023)Third quarter 2024 results: EPS: US$0.92 (up from US$0.16 in 3Q 2023). Revenue: US$565.0m (up 5.3% from 3Q 2023). Net income: US$544.0m (up US$471.9m from 3Q 2023). Profit margin: 96% (up from 13% in 3Q 2023). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
Declared Dividend • Oct 21Second quarter dividend of US$0.21 announcedShareholders will receive a dividend of US$0.21. Ex-date: 15th November 2024 Payment date: 10th December 2024 Dividend yield will be 3.1%, which is higher than the industry average of 2.4%. Sustainability & Growth Dividend is covered by earnings (55% earnings payout ratio) but not covered by cash flows (124% cash payout ratio). The dividend has increased by an average of 8.8% per year over the past 4 years and payments have been stable during that time. EPS is expected to grow by 41% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • Oct 17Royalty Pharma plc to Report Q3, 2024 Results on Nov 06, 2024Royalty Pharma plc announced that they will report Q3, 2024 results Pre-Market on Nov 06, 2024
お知らせ • Oct 11Royalty Pharma Declares Fourth Quarter 2024 Dividend, Payable on December 10, 2024Royalty Pharma plc has approved the payment of a dividend for the fourth quarter of 2024 of $0.21 per Class A ordinary share. The dividend will be paid on December 10, 2024, to shareholders of record at the close of business on November 15, 2024.
Upcoming Dividend • Aug 09Upcoming dividend of US$0.21 per shareEligible shareholders must have bought the stock before 16 August 2024. Payment date: 13 September 2024. Payout ratio is a comfortable 55% and the cash payout ratio is 92%. Trailing yield: 3.2%. Lower than top quartile of German dividend payers (4.9%). Higher than average of industry peers (1.1%).
お知らせ • Jul 24Royalty Pharma plc Appoints Molly Sawaya as Executive Vice President, Head of Human CapitalRoyalty Pharma plc announced the appointment of Molly Sawaya as Executive Vice President, Head of Human Capital. Molly joins Royalty Pharma from Hudson Bay Capital, where she was a Managing Director and Head of Colleague Experience, responsible for designing and delivering the firm’s Human Resources (HR) agenda, including onboarding, colleague engagement, professional development, compensation and benefits. Previously, Molly held a number of global HR roles of increasing responsibility at QBE Insurance Group, Perpetual Limited and National Australia Bank. Molly received her Bachelor of Arts and Master of Applied Science degrees in Psychology from the University of Sydney.
Declared Dividend • Jul 22First quarter dividend of US$0.21 announcedShareholders will receive a dividend of US$0.21. Ex-date: 16th August 2024 Payment date: 13th September 2024 Dividend yield will be 3.1%, which is higher than the industry average of 2.4%. Sustainability & Growth Dividend is well covered by both earnings (45% earnings payout ratio) and cash flows (49% cash payout ratio). The dividend has increased by an average of 8.8% per year over the past 4 years and payments have been stable during that time. EPS is expected to grow by 45% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • Jul 20Royalty Pharma plc to Report Q2, 2024 Results on Aug 08, 2024Royalty Pharma plc announced that they will report Q2, 2024 results Pre-Market on Aug 08, 2024
お知らせ • Jul 18Royalty Pharma plc Declares Dividend for the Third Quarter of 2024, Payable on September 13, 2024Royalty Pharma plc has approved the payment of a dividend for the third quarter of 2024 of $0.21 per Class A ordinary share. The dividend will be paid on September 13, 2024, to shareholders of record at the close of business on August 16, 2024.
お知らせ • Jun 19Royalty Pharma plc Announces the Resignation of Rory Balfour Riggs as DirectorRoyalty Pharma plc announced the resignation of Rory Balfour Riggs as director with effect from 6 June 2024.
お知らせ • Jun 18Royalty Pharma plc Announces Resignation of Mario Germano Giuliani as DirectorRoyalty Pharma plc announced resignation of Mario Germano Giuliani as director with effect from 6 June 2024.
Reported Earnings • May 09First quarter 2024 earnings released: EPS: US$0.011 (vs US$0.77 in 1Q 2023)First quarter 2024 results: EPS: US$0.011 (down from US$0.77 in 1Q 2023). Revenue: US$568.0m (down 17% from 1Q 2023). Net income: US$5.00m (down 99% from 1Q 2023). Profit margin: 0.9% (down from 50% in 1Q 2023). Revenue is forecast to grow 8.3% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany.
お知らせ • Apr 28Royalty Pharma plc, Annual General Meeting, Jun 06, 2024Royalty Pharma plc, Annual General Meeting, Jun 06, 2024, at 09:00 Eastern Daylight. Location: 110 East 59 th Street New York New York United States Agenda: To consider election of each of the eight director nominees listed in the accompanying Proxy Statement by separate ordinary resolutions; to approve on a non-binding advisory basis the compensation of named executive officers; to ratify on a non-binding advisory basis the appointment of Ernst & Young LLP, as independent registered public accounting firm; to approve receipt of our U.K. Annual Report and Accounts for the fiscal year ended December 31, 2023; and to consider other matters.
Declared Dividend • Apr 23Fourth quarter dividend of US$0.21 announcedShareholders will receive a dividend of US$0.21. Ex-date: 16th May 2024 Payment date: 14th June 2024 Dividend yield will be 3.0%, which is higher than the industry average of 2.4%. Sustainability & Growth Dividend is covered by both earnings (32% earnings payout ratio) and cash flows (58% cash payout ratio). The dividend has increased by an average of 8.8% per year over the past 4 years and payments have been stable during that time. EPS is expected to grow by 22% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • Apr 17Royalty Pharma plc Declares Dividend for the Second Quarter of 2024, Payable on June 14, 2024The board of directors of Royalty Pharma plc has approved the payment of a dividend for the second quarter of 2024 of $0.21 per Class A ordinary share. The dividend will be paid on June 14, 2024, to shareholders of record at the close of business on May 17, 2024.
お知らせ • Apr 04Royalty Pharma plc to Report Q1, 2024 Results on May 09, 2024Royalty Pharma plc announced that they will report Q1, 2024 results on May 09, 2024
Reported Earnings • Feb 16Full year 2023 earnings released: EPS: US$2.54 (vs US$0.098 in FY 2022)Full year 2023 results: EPS: US$2.54 (up from US$0.098 in FY 2022). Revenue: US$2.35b (up 5.2% from FY 2022). Net income: US$1.13b (up US$1.09b from FY 2022). Profit margin: 48% (up from 1.9% in FY 2022). Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Pharmaceuticals industry in Germany.
Upcoming Dividend • Feb 08Upcoming dividend of US$0.21 per share at 2.9% yieldEligible shareholders must have bought the stock before 15 February 2024. Payment date: 15 March 2024. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 2.9%. Lower than top quartile of German dividend payers (5.2%). Higher than average of industry peers (2.6%).
お知らせ • Feb 07Novartis data42 AG entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG (XTRA:MOR) for €2.3 billion.Novartis data42 AG entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG (XTRA:MOR) for €2.3 billion on February 5, 2024. Under the agreed transaction, €68 per share will be paid. The agreement is unanimously approved by the Board of Directors of both companies. The transaction is subject to customary closing conditions, including acceptance of the takeover offer by at least 65% of MorphoSys AG’s outstanding shares and receipt of regulatory approvals and is expected to close in the first half of 2024. Centerview Partners is acting as lead financial advisor and Graham Robinson, Faiz Ahmad, Brian V. Breheny, Timothy F. Nelson, Maria Raptis, Resa K. Schlossberg, Jan Bauer, Matthias Horbach, Stephan Hutter and Caspar Schmelzer of Skadden, Arps, Slate, Meagher & Flom LLP acted as legal advisor to MorphoSys AG. Jenny Hochenberg, of Freshfields Bruckhaus Deringer US LLP acted as legal advisor to Novartis AG.
お知らせ • Jan 31Royalty Pharma plc to Report Q4, 2023 Results on Feb 15, 2024Royalty Pharma plc announced that they will report Q4, 2023 results Pre-Market on Feb 15, 2024
Declared Dividend • Jan 29Third quarter dividend of US$0.21 announcedShareholders will receive a dividend of US$0.21. Ex-date: 15th February 2024 Payment date: 15th March 2024 Dividend yield will be 2.9%, which is higher than the industry average of 2.3%. Sustainability & Growth Dividend is not covered by earnings (191% earnings payout ratio). However, it is well covered by cash flows (35% cash payout ratio). The dividend has increased by an average of 12% per year over the past 3 years and payments have been stable during that time. The company's earnings per share (EPS) would need to grow by 113% to bring the payout ratio under control. EPS is expected to grow by 104% over the next 3 years, which means the dividend may need to be reduced to reach a sustainable payout ratio.
お知らせ • Jan 19Royalty Pharma plc Declares Dividend for the First Quarter of 2024, Payable on March 15, 2024Royalty Pharma plc announced that its board of directors has declared a dividend for the first quarter of 2024 of $0.21 per Class A share, reflecting a 5% increase in the company’s quarterly dividend over the previous quarter’s dividend. The dividend will be paid on March 15, 2024 to shareholders of record at the close of business on February 16, 2024.
Recent Insider Transactions • Jan 01Director recently sold €6.4m worth of stockOn the 28th of December, Mario Giuliani sold around 252k shares on-market at roughly €25.43 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €18m. Insiders have been net sellers, collectively disposing of €26m more than they bought in the last 12 months.
Recent Insider Transactions • Dec 18Director recently sold €18m worth of stockOn the 14th of December, Mario Giuliani sold around 672k shares on-market at roughly €26.31 per share. This transaction amounted to 2.0% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €19m more than they bought in the last 12 months.
Reported Earnings • Nov 09Third quarter 2023 earnings released: EPS: US$0.16 (vs US$0.33 in 3Q 2022)Third quarter 2023 results: EPS: US$0.16 (down from US$0.33 in 3Q 2022). Revenue: US$536.3m (down 6.5% from 3Q 2022). Net income: US$72.1m (down 49% from 3Q 2022). Profit margin: 13% (down from 25% in 3Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 3.0% growth forecast for the Pharmaceuticals industry in Germany.
Upcoming Dividend • Nov 09Upcoming dividend of US$0.20 per share at 2.9% yieldEligible shareholders must have bought the stock before 16 November 2023. Payment date: 15 December 2023. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 2.9%. Lower than top quartile of German dividend payers (5.1%). Higher than average of industry peers (2.6%).
お知らせ • Sep 22Royalty Pharma Appoints Eric Schneider as Chief Technology OfficerRoyalty Pharma plc announced the appointment of Eric Schneider as Senior Vice President, Chief Technology Officer. Eric will also join Royalty Pharma’s Senior Leadership Committee. Eric joins Royalty Pharma from Verisk, a global leader in data-driven analytic insights and solutions, where he was a Senior Vice President, Chief Data Officer and Chief Technology Officer, and a member of the Executive Leadership Team. During his tenure at Verisk, he led their migration to the cloud, mainframe modernization strategy and Data Governance and Data Strategy Team. Prior to Verisk, Mr. Schneider held senior IT leadership roles at Moody’s Investor Services, Barclay’s Capital, AIG and McKinsey & Company.
Recent Insider Transactions • Aug 14Executive VP & CFO recently sold €2.1m worth of stockOn the 10th of August, Terrance Coyne sold around 75k shares on-market at roughly €27.90 per share. This transaction amounted to 8.2% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €6.1m. Terrance has been a net seller over the last 12 months, reducing personal holdings by €4.2m.
Upcoming Dividend • Aug 10Upcoming dividend of US$0.20 per share at 2.6% yieldEligible shareholders must have bought the stock before 17 August 2023. Payment date: 15 September 2023. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 2.6%. Lower than top quartile of German dividend payers (4.7%). In line with average of industry peers (2.5%).
Reported Earnings • Aug 09Second quarter 2023 earnings released: EPS: US$0.51 (vs US$0.70 in 2Q 2022)Second quarter 2023 results: EPS: US$0.51 (down from US$0.70 in 2Q 2022). Revenue: US$538.0m (flat on 2Q 2022). Net income: US$228.0m (down 25% from 2Q 2022). Profit margin: 42% (down from 57% in 2Q 2022). Revenue is forecast to grow 7.9% p.a. on average during the next 3 years, compared to a 2.9% growth forecast for the Pharmaceuticals industry in Germany.
Board Change • Aug 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. 1 highly experienced director. Independent Director Dave Hodgson was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jul 18Royalty Pharma plc Declares Dividend on Class A Ordinary Shares for the Third Quarter of 2023, Payable on September 15, 2023The board of directors of Royalty Pharma plc has approved the payment of a dividend for the third quarter of 2023 of $0.20 per Class A ordinary share. The dividend will be paid on September 15, 2023, to shareholders of record at the close of business on August 18, 2023.
Recent Insider Transactions • Jul 17Executive VP & CFO recently sold €2.1m worth of stockOn the 13th of July, Terrance Coyne sold around 75k shares on-market at roughly €27.70 per share. This transaction amounted to 6.3% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €6.1m. This was Terrance's only on-market trade for the last 12 months.
Recent Insider Transactions • Jun 30Founder recently bought €3.5m worth of stockOn the 28th of June, Pablo Legorreta bought around 130k shares on-market at roughly €27.04 per share. This transaction amounted to 3.6% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth €7.1m. Pablo has been a buyer over the last 12 months, purchasing a net total of €18m worth in shares.
お知らせ • Jun 30Royalty Pharma plc to Report Q2, 2023 Results on Aug 08, 2023Royalty Pharma plc announced that they will report Q2, 2023 results on Aug 08, 2023
Recent Insider Transactions • Jun 11Insider recently sold €6.1m worth of stockOn the 6th of June, George Lloyd sold around 192k shares on-market at roughly €31.53 per share. This transaction amounted to 17% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €191m more than they bought in the last 12 months.
Recent Insider Transactions • May 21Founder recently bought €7.1m worth of stockOn the 17th of May, Pablo Legorreta bought around 230k shares on-market at roughly €30.83 per share. This transaction amounted to 7.3% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Pablo's only on-market trade for the last 12 months.
Upcoming Dividend • May 11Upcoming dividend of US$0.20 per share at 2.4% yieldEligible shareholders must have bought the stock before 18 May 2023. Payment date: 15 June 2023. Payout ratio and cash payout ratio are on the higher end at 76% and 91% respectively. Trailing yield: 2.4%. Lower than top quartile of German dividend payers (4.6%). In line with average of industry peers (2.5%).
Reported Earnings • May 09First quarter 2023 earnings released: EPS: US$0.77 (vs US$0.12 in 1Q 2022)First quarter 2023 results: EPS: US$0.77 (up from US$0.12 in 1Q 2022). Revenue: US$684.0m (up 22% from 1Q 2022). Net income: US$341.0m (up US$289.2m from 1Q 2022). Profit margin: 50% (up from 9.2% in 1Q 2022). Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany.
Recent Insider Transactions • Apr 02Director recently sold €4.7m worth of stockOn the 30th of March, Rory Riggs sold around 140k shares on-market at roughly €33.29 per share. This transaction amounted to 8.7% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €219m more than they bought in the last 12 months.
Recent Insider Transactions • Mar 02Insider recently sold €879k worth of stockOn the 23rd of February, George Lloyd sold around 25k shares on-market at roughly €35.18 per share. This transaction amounted to 2.0% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €3.5m. Insiders have been net sellers, collectively disposing of €212m more than they bought in the last 12 months.
Reported Earnings • Feb 16Full year 2022 earnings released: EPS: US$0.097 (vs US$1.49 in FY 2021)Full year 2022 results: EPS: US$0.097 (down from US$1.49 in FY 2021). Revenue: US$2.24b (down 2.3% from FY 2021). Net income: US$43.0m (down 93% from FY 2021). Profit margin: 1.9% (down from 27% in FY 2021). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Pharmaceuticals industry in Germany.
Upcoming Dividend • Feb 08Upcoming dividend of US$0.20 per share at 2.1% yieldEligible shareholders must have bought the stock before 15 February 2023. Payment date: 15 March 2023. Payout ratio is a comfortable 64% and the cash payout ratio is 81%. Trailing yield: 2.1%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (2.6%).
お知らせ • Jan 16Royalty Pharma plc to Report Q4, 2022 Results on Feb 15, 2023Royalty Pharma plc announced that they will report Q4, 2022 results on Feb 15, 2023
お知らせ • Jan 10Royalty Pharma Declares First Quarter 2023 Dividend, Payable on March 15, 2023Royalty Pharma plc declared a dividend for the first quarter of 2023 of $0.20 per Class A share, reflecting a 5.3% increase in the company's quarterly dividend over the previous quarter's dividend. The dividend will be paid on March 15, 2023 to shareholders of record at the close of business on February 16, 2023.
お知らせ • Dec 17Royalty Pharma Announces Expansion of Senior Leadership TeamRoyalty Pharma plc announced the expansion of its senior leadership team. This expansion highlights Royalty Pharma’s success in developing a talented, diverse and experienced leadership team responsible for formulating and executing on its mission to accelerate innovation and transform patient lives. The following promotions are effective January 1, 2023, and each individual will join the Senior Leadership Committee: Sara Klymkowskywill be promoted to Senior Vice President, Research & Investments. Sara has been an integral member of the Research & Investments team since joining Royalty Pharma in 2012. She has played a key role in executing many of Royalty Pharma’s most important transactions, including investments in the Vertex cystic fibrosis franchise, Tysabri and Trelegy. Brienne Kugler will be promoted to Senior Vice President, Research & Investments. Brienne has been a key member of the Research & Investments team since joining Royalty Pharma in 2014. She has played a major role in executing many of Royalty Pharma’s most important transactions, including multiple Biohaven investments, Tremfya and Evrysdi. Alessandra Sassun will be promoted to Senior Vice President, Head of Human Capital. Alessandra joined Royalty Pharma in 2020 and is responsible for overseeing Royalty Pharma’s human resource planning, professional development and performance management.
Recent Insider Transactions • Dec 16Director recently sold €2.4m worth of stockOn the 12th of December, Rory Riggs sold around 60k shares on-market at roughly €39.91 per share. This transaction amounted to 35% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €33m. Insiders have been net sellers, collectively disposing of €213m more than they bought in the last 12 months.
Recent Insider Transactions • Dec 07Director recently sold €15m worth of stockOn the 2nd of December, Mario Giuliani sold around 363k shares on-market at roughly €42.00 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €43m. Insiders have been net sellers, collectively disposing of €207m more than they bought in the last 12 months.
Board Change • Nov 16High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. 1 highly experienced director. Founder, Chairman of the Board & CEO Pablo Legorreta is the most experienced director on the board, commencing their role in 1996. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Upcoming Dividend • Nov 10Upcoming dividend of US$0.19 per shareEligible shareholders must have bought the stock before 17 November 2022. Payment date: 15 December 2022. Payout ratio is a comfortable 64% and the cash payout ratio is 81%. Trailing yield: 1.8%. Lower than top quartile of German dividend payers (5.0%). Lower than average of industry peers (2.7%).
Reported Earnings • Nov 09Third quarter 2022 earnings released: EPS: US$0.33 (vs US$0.24 in 3Q 2021)Third quarter 2022 results: EPS: US$0.33 (up from US$0.24 in 3Q 2021). Revenue: US$573.5m (down 2.1% from 3Q 2021). Net income: US$142.7m (up 40% from 3Q 2021). Profit margin: 25% (up from 17% in 3Q 2021). The increase in margin was driven by lower expenses. Revenue is forecast to grow 8.4% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Pharmaceuticals industry in Germany.
お知らせ • Oct 18Royalty Pharma Declares Fourth Quarter 2022 Dividend, Payable on December 15, 2022Royalty Pharma plc has approved the payment of a dividend for the fourth quarter of 2022 of $0.19 per Class A ordinary share. The dividend will be paid on December 15, 2022, to shareholders of record at the close of business on November 18, 2022.
お知らせ • Oct 13Royalty Pharma plc Announces Executive ChangesRoyalty Pharma plc announced an expansion of its leadership team. Art McGivern has joined Royalty Pharma as Executive Vice President, Investments & General Counsel and George Lloyd has been promoted to Executive Vice President, Investments & Chief Legal Officer. Art McGivern joins Royalty Pharma from Goodwin Procter where he was a partner in its Life Sciences Group. He has been Royalty Pharma's lead outside lawyer on substantially all investment transactions since 2012. Art brings experience across public and private securities offerings, mergers and acquisitions, royalty-based financings and other complex transactions, and has advised companies in their ongoing corporate matters. Art has a BSCE from Tufts University and a JD from Boston University.George Lloyd leads the legal and compliance functions at Royalty Pharma. He joined Royalty Pharma in 2011 after representing Royalty Pharma on all transactional work since 2006. George was previously a partner in Goodwin Procter'sPrivate Equity Group. He has an AB from Princeton University and a JD from New York University Law School.
お知らせ • Oct 05Royalty Pharma plc to Report Q3, 2022 Results on Nov 08, 2022Royalty Pharma plc announced that they will report Q3, 2022 results at 9:30 AM, US Eastern Standard Time on Nov 08, 2022
Recent Insider Transactions • Sep 11Director recently sold €43m worth of stockOn the 8th of September, Mario Giuliani sold around 998k shares on-market at roughly €42.83 per share. This transaction amounted to 1.7% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €85m more than they bought in the last 12 months.
Recent Insider Transactions • Aug 13Director recently sold €1.9m worth of stockOn the 9th of August, Rory Riggs sold around 45k shares on-market at roughly €42.75 per share. In the last 3 months, they made an even bigger sale worth €5.6m. Insiders have been net sellers, collectively disposing of €43m more than they bought in the last 12 months.
Upcoming Dividend • Aug 11Upcoming dividend of US$0.19 per shareEligible shareholders must have bought the stock before 18 August 2022. Payment date: 15 September 2022. Payout ratio is a comfortable 67% and the cash payout ratio is 100%. Trailing yield: 1.7%. Lower than top quartile of German dividend payers (4.5%). Lower than average of industry peers (2.7%).
Reported Earnings • Aug 05Second quarter 2022 earnings released: EPS: US$0.70 (vs US$1.08 in 2Q 2021)Second quarter 2022 results: EPS: US$0.70 (down from US$1.08 in 2Q 2021). Revenue: US$536.0m (down 3.4% from 2Q 2021). Net income: US$305.0m (down 31% from 2Q 2021). Profit margin: 57% (down from 79% in 2Q 2021). The decrease in margin was primarily driven by higher expenses. Over the next year, revenue is forecast to grow 5.3%, compared to a 8.0% growth forecast for the industry in Germany.
お知らせ • Jul 16Royalty Pharma plc Declares Third Quarter 2022 Dividend, to Be Paid on September 15, 2022The board of directors of Royalty Pharma plc has approved the payment of a dividend for the third quarter of 2022 of $0.19 per Class A ordinary share. The dividend will be paid on September 15, 2022, to shareholders of record at the close of business on August 19, 2022.
お知らせ • Jul 02Royalty Pharma plc to Report Q2, 2022 Results on Aug 04, 2022Royalty Pharma plc announced that they will report Q2, 2022 results at 9:30 AM, US Eastern Standard Time on Aug 04, 2022
Recent Insider Transactions • Jul 01Director recently sold €1.2m worth of stockOn the 29th of June, Rory Riggs sold around 30k shares on-market at roughly €40.28 per share. In the last 3 months, they made an even bigger sale worth €5.6m. Insiders have been net sellers, collectively disposing of €41m more than they bought in the last 12 months.
お知らせ • Jun 25Royalty Pharma plc Announces Directorate ChangeRoyalty Pharma plc announced the resignation of William Edward Ford and appointment of David Hodgson with effect from 23 June 2022.
Recent Insider Transactions • Jun 12Insider recently sold €3.9m worth of stockOn the 8th of June, James Reddoch sold around 100k shares on-market at roughly €38.70 per share. In the last 3 months, there was an even bigger sale from another insider worth €5.6m. Insiders have been net sellers, collectively disposing of €40m more than they bought in the last 12 months.
Recent Insider Transactions • May 25Director recently sold €5.6m worth of stockOn the 20th of May, Rory Riggs sold around 150k shares on-market at roughly €37.37 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €43m more than they bought in the last 12 months.
Upcoming Dividend • May 12Upcoming dividend of US$0.19 per shareEligible shareholders must have bought the stock before 19 May 2022. Payment date: 15 June 2022. Payout ratio is a comfortable 49% but the company is paying out more than the cash it is generating. Trailing yield: 2.0%. Lower than top quartile of German dividend payers (4.2%). Lower than average of industry peers (2.7%).
Reported Earnings • May 06First quarter 2022 earnings released: EPS: US$0.12 (vs US$0.18 in 1Q 2021)First quarter 2022 results: EPS: US$0.12 (down from US$0.18 in 1Q 2021). Revenue: US$563.0m (down 1.7% from 1Q 2021). Net income: US$52.0m (down 25% from 1Q 2021). Profit margin: 9.2% (down from 12% in 1Q 2021). The decrease in margin was primarily driven by lower revenue. Over the next year, revenue is forecast to grow 1.1%, compared to a 8.1% growth forecast for the industry in Germany.
Board Change • Apr 27High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. 1 highly experienced director. Founder, Chairman of the Board & CEO Pablo Legorreta is the most experienced director on the board, commencing their role in 1996. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Apr 19Royalty Pharma plc Declares Second Quarter 2022 Dividend, Payable on June 15, 2022The board of directors of Royalty Pharma plc has approved the payment of a dividend for the second quarter of 2022 of $0.19 per Class A ordinary share. The dividend will be paid on June 15, 2022, to shareholders of record at the close of business on May 20, 2022.
お知らせ • Apr 04Royalty Pharma plc to Report Q1, 2022 Results on May 05, 2022Royalty Pharma plc announced that they will report Q1, 2022 results on May 05, 2022
